story of the week
Cilta-Cel vs Standard Care for Lenalidomide-Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
N. Engl. J. Med 2023 Jun 05;[EPub Ahead of Print], J San-Miguel, B Dhakal, K Yong, A Spencer, S Anguille, MV Mateos, C Fernández de Larrea, J Martínez-López, P Moreau, C Touzeau, X Leleu, I Avivi, M Cavo, T Ishida, SJ Kim, W Roeloffzen, NWCJ van de Donk, D Dytfeld, S Sidana, LJ Costa, A Oriol, R Popat, AM Khan, YC Cohen, PJ Ho, J Griffin, N Lendvai, C Lonardi, A Slaughter, JM Schecter, CC Jackson, K Connors, K Li, E Zudaire, D Chen, J Gilbert, TM Yeh, S Nagle, E Florendo, L Pacaud, N Patel, SJ Harrison, H EinseleFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.